ASCO 2025: Chemo-Immunotherapy Combined with Stereotactic Radiation Shows Promise in Pancreatic Cancer

Pancreatic cancer continues to pose a significant clinical challenge, with a dismal 5-year survival rate of approximately 10% across all stages. At ASCO 2025, Dr. Inna Markovna Chen from Herlev and Gentofte University Hospital presented new data highlighting the potential of a combined chemo-immunotherapy regimen with stereotactic body radiation therapy (SBRT). The findings demonstrated manageable toxicity and promising resection rates.
In this MEDtalk, Dr. Chen emphasized that this multimodal approach may contribute to improved clinical outcomes in a disease where treatment options remain limited.